The Goldman Sachs Group Has Lowered Expectations for uniQure (NASDAQ:QURE) Stock Price

uniQure (NASDAQ:QURE) had its target price dropped by equities researchers at The Goldman Sachs Group from $10.00 to $9.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 26.76% from the company’s current price.

Several other equities research analysts also recently weighed in on the stock. Royal Bank of Canada decreased their price target on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday. Raymond James restated an “outperform” rating and set a $20.00 price target on shares of uniQure in a report on Thursday, October 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 target price on shares of uniQure in a research note on Wednesday. StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Thursday, October 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of uniQure in a research report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $17.00.

uniQure Trading Up 17.2 %

Shares of NASDAQ:QURE traded up $1.04 during mid-day trading on Wednesday, reaching $7.10. 920,087 shares of the company’s stock were exchanged, compared to its average volume of 1,409,975. The firm has a market capitalization of $345.77 million, a price-to-earnings ratio of -1.20 and a beta of 0.90. The business’s fifty day moving average price is $5.68 and its 200-day moving average price is $5.78. The company has a debt-to-equity ratio of 1.06, a quick ratio of 7.36 and a current ratio of 7.36. uniQure has a twelve month low of $3.73 and a twelve month high of $11.35.

Institutional Trading of uniQure

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of uniQure by 11.4% in the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after buying an additional 109,740 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of uniQure by 133.1% in the 1st quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after purchasing an additional 350,291 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in uniQure by 74.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 157,312 shares of the biotechnology company’s stock valued at $818,000 after buying an additional 66,958 shares during the period. Assenagon Asset Management S.A. boosted its position in uniQure by 49.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock valued at $1,338,000 after buying an additional 89,400 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in uniQure by 4.3% during the 1st quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock valued at $3,831,000 after buying an additional 30,054 shares during the period. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.